Gastroenterology
Volume 135, Issue 5 , Pages 1561-1567 , November 2008

Silibinin Is a Potent Antiviral Agent in Patients With Chronic Hepatitis C Not Responding to Pegylated Interferon/Ribavirin Therapy

  • Peter Ferenci

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • Corresponding Author InformationAddress requests for reprints to: Peter Ferenci, MD, Prof, Universitätsklinik für Innere Medizin III, Medical University of Vienna, AKH, Waehringer Guertel 18-20, A 1090 Wien, Austria. fax: (43) 1 0 40400 4735
    • ,
  • Thomas–Matthias Scherzer

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Heidrun Kerschner

      Affiliations

    • Clinical Institute of Virology, Medical University of Vienna, Austria
    • ,
  • Karoline Rutter

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Sandra Beinhardt

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Harald Hofer

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Maximilian Schöniger–Hekele

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria
    • ,
  • Heidemarie Holzmann

      Affiliations

    • Clinical Institute of Virology, Medical University of Vienna, Austria
    • ,
  • Petra Steindl–Munda

      Affiliations

    • Internal Medicine 3, Department of Gastroenterology and Hepatology, Medical University of Vienna, Austria

Received 28 May 2008 ,Accepted 24 July 2008.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Trial registered at: www.clinicaltrials.gov: NCT00684268.

 The authors disclose the following: Conflicts of interest: P. Ferenci: Roche, Basel, CH; member of the Global Advisory Board and of the speakers bureau and receives financial support for clinical studies. All other authors have no conflicts of interest.

 Supported by an unrestricted research grant by Roche Austria, and silibinin (Legalon Sil) and silimaryin (Legalon) were provided by Rottapharm-Madaus, Köln, Germany. None of the companies was involved in the design, conduct, and evaluation of this protocol.

PII: S0016-5085(08)01412-1

doi: 10.1053/j.gastro.2008.07.072

Gastroenterology
Volume 135, Issue 5 , Pages 1561-1567 , November 2008

Article Tools

* Image Usage & Resolution